Endpoints News
Acelyrin founder Shao-Lee Lin emerges at Cue Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Th Fri
1 May, 2026
ENDPOINTS at #ASCO26
ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.
presented by mAbxience From lab to life
Glob­al part­ner­ing be­fore the term sheet: de-risk­ing bio­phar­ma deals from day one
spotlight
bioregnum
top stories
1. Summit slips on ivonescimab's apparent interim miss in sign of investor frustration
2. Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China
3. Amgen files update to Tavneos label as FDA escalates push to withdraw 
4.
news briefing
FDA approves Auvelity for Alzheimer's agitation; Esperion goes private in $1.1B deal
5. J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
6. Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut
7.
peer review
Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit
8. Bristol Myers' Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
9. House panel calls for banning China data from FDA drug trial applications
10. Court dismisses part of Lilly lawsuit against compounder Empower, but some claims can proceed
11. Supreme Court questions how far generics makers can go when marketing 'skinny label' drugs
more stories
• 
Alex Hoffman
.

Summit Therapeutics looked like it had the next big thing in cancer drug development with its PD-1xVEGF bispecific ivonescimab. But the leaks in the ceiling have been multiplying — and investors are none too happy. Max Gelman has the story on Summit's latest stock drop. Have a great weekend!
.
Alex Hoffman
Senior Copy Editor, Endpoints News
1
by Max Gelman

Sum­mit Ther­a­peu­tics’ stock price SMMT tum­bled near­ly 20% af­ter the clos­ing bell Thurs­day af­ter­noon, fol­low­ing an ap­par­ent sta­tis­ti­cal miss in part of a Phase 3...

Read full story
Shao-Lee Lin, new Cue Biopharma CEO
2
by Lei Lei Wu

Cue Bio­phar­ma an­nounced a re­boot Thurs­day af­ter­noon, bring­ing in no­table biotech ex­ec­u­tive Shao-Lee Lin as well as a new al­ler­gy as­set de­vel­oped in Tai­wan and...

Read full story
3
by Nicole DeFeudis

Am­gen has tak­en steps to up­date its Tavneos la­bel amid an on­go­ing bat­tle with the FDA.

The com­pa­ny filed a sup­ple­menton Wednes­day that would...

Read full story
US Pharma and Biotech Summit - May 14, 2026
US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.
News Briefing: Quick hits from the biopharma web
4